Group 1 - The company has entered into a distribution and supply agreement with PT Ferron Par Pharmaceuticals for the commercialization of BRIMOCHOL™ PF in Indonesia, granting PT Ferron exclusive rights for import, promotion, distribution, marketing, and sales of the product [1] - The company will receive an upfront payment and may earn additional milestone payments based on specific achievements [1] - The developer of BRIMOCHOL™ PF, Tenpoint Therapeutics, announced that the FDA has accepted the new drug application for the product, with a review deadline set for January 28, 2026 [1] Group 2 - BRIMOCHOL™ PF is a preservative-free, experimental eye drop intended to correct near vision loss due to aging, and is part of a multi-center, randomized, double-blind study involving 629 participants across 47 trial centers in the U.S. [2] - The study compares the safety and efficacy of BRIMOCHOL™ PF with other treatments for presbyopia [2] Group 3 - PT Ferron Par Pharmaceuticals, a member of the Dexa Group, has been operating since 2001 and is one of the top 15 largest pharmaceutical companies in Indonesia according to IQVIA data [3] - The company has received recognition from regulatory agencies in the UK and Portugal, enhancing its market influence and operational capabilities through a diverse product portfolio and strong strategic partnerships [3]
兆科眼科-B(06622)就于印度尼西亚商业化BRIMOCHOL™ PF与PT FERRON订立分销协议